L26/P-425 Fertility preservation and recurrence risk in women with borderline and malignant ovarian tumours: a single tertiary centre experience
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von L.V. De Braud und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does ovarian stimulation for oocyte or embryo cryopreservation increase recurrence risk in women with borderline or malignant ovarian tumours undergoing fertility preservation? Summary answer Ovarian stimulation was not associated with increased recurrence risk in women with borderline and early-stage ovarian cancer following fertility-sparing surgery. What is known already Fertility-sparing surgery is an established approach for women of reproductive age diagnosed with borderline and early-stage ovarian malignancies1. However, disease recurrence—often requiring additional ovarian surgery—has been reported in approximately 10–30% of cases2. Fertility preservation (FP), including oocyte or ovarian tissue cryopreservation, should therefore be discussed with these patients. Although controlled ovarian stimulation is generally considered safe, evidence regarding its impact on recurrence risk remains limited, contributing to ongoing clinical hesitation. Existing studies predominantly focus on borderline tumours in subfertile populations, leaving uncertainty about oncological safety in a broader and more heterogeneous cohort3-4. Study design, size, duration This retrospective cohort study included reproductive-age women who underwent fertility-sparing surgery between 2010 and 2025. Data were obtained from integrated clinical databases of the gynaecologic oncology and reproductive medicine units. Overall, 165 records were reviewed; 158 were included in the final analysis after excluding seven patients without available follow-up data. Participants/materials, setting, methods The study was conducted at a single tertiary centre. Postpubertal women younger than 43 years at diagnosis were included. Data collected included surgical approach, disease stage, histology, post-surgical AMH, and follow-up outcomes (recurrence and fertility). Recurrence rates were compared between women who underwent ovarian stimulation and those who did not. Relative risk (RR) with 95% confidence intervals was calculated. The primary outcome was recurrence risk; secondary outcomes included FP counselling rates, utilisation, and pregnancy. Main results and the role of chance Pathology confirmed borderline tumours in 76 women (48.1%), germ cell tumours in 44 (27,8%), sex cord-stromal tumours in 21 (13,2%) and malignant epithelial ovarian tumours in 17 (10.7%). Disease was predominantly unilateral (90.5%) and stage I (82.9%). Mean age at diagnosis was 26.2 ± 7.9 years. Fertility preservation was offered to 58.8% of women, and 35% proceeded with FP. Seven patients (4.4%) underwent opportunistic ovarian tissue cryopreservation during surgery for potential future in-vitro maturation, while 48 (30.4%) underwent ovarian stimulation for oocyte or embryo cryopreservation. Mean pre-stimulation AMH was 10.5 ± 6.9, and the mean number of mature oocytes cryopreserved per patient was 7.7 ± 5.2. Median follow-up was 63 months (IQR 29–101). Overall, 32 women (20.3%) experienced recurrence after initial surgery. Recurrence occurred in 18.9% of women who did not undergo ovarian stimulation compared with 12.5% of those who did. No statistically significant increase in recurrence risk was observed following stimulation (RR 0.65; 95% CI 0.29–1.48), and time to recurrence was similar between groups. Among women who underwent FP, four (8.3%) returned to use their gametes, while three (6.2%) achieved spontaneous pregnancies. Limitations, reasons for caution The primary limitation is the retrospective design. Although this represents one of the largest cohorts reported, the sample size remains modest. Additionally, follow-up was shorter than five years for approximately half of the patients, potentially resulting in underestimation of recurrence risk. Wider implications of the findings Oocyte cryopreservation appear safe and should be offered to patients with ovarian tumours eligible for fertility-sparing surgery. The recurrence rate of nearly 20% in the non-stimulated group highlights missed opportunities for these women to preserve their fertility. Counselling for fertility preservation and more robust long-term reproductive outcome data are needed. Trial registration number No
Zitieren
APA
Braud, L. D., MacDonald, N., Tesfai, F., Pearce, M., & Yasmin, E. (2026). L26/P-425 Fertility preservation and recurrence risk in women with borderline and malignant ovarian tumours: a single tertiary centre experience. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.759
Vancouver
Braud LD, MacDonald N, Tesfai F, Pearce M, Yasmin E. L26/P-425 Fertility preservation and recurrence risk in women with borderline and malignant ovarian tumours: a single tertiary centre experience. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.759
BibTeX
@article{Braud2026,
author = {Braud, L.V. De and MacDonald, N. and Tesfai, F. and Pearce, M. and Yasmin, E.},
title = {L26/P-425 Fertility preservation and recurrence risk in women with borderline and malignant ovarian tumours: a single tertiary centre experience},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.759}
}
EUVIMED